Opinion|Videos|October 7, 2024
COSMOS-CRC-01: Study Design and Methodology
Author(s)Yoshiaki Nakamura, MD, PhD
Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study was designed to evaluate the efficacy of ctDNA analysis for MRD detection, outlining the rationale for patient enrollment, the timing of plasma sample collection, and the implications for monitoring disease post surgery and during adjuvant chemotherapy.
Advertisement
Episodes in this series
1. Please explain the rationale, enrollment criteria, objectives, and methodology of the COSMOS-CRC-01 study.
2. What patient and/or disease factors motivated the decision to obtain the first plasma sample for ctDNA analysis at postoperative day28?
- In your experience, how soon after resection for R0 (ie, microscopically margin negative) stage II to III CRC can ctDNA sequencing be conducted and reliably detect potential MRD at the micrometastatic level?
3. Please review the timing of pre-and postadjuvant chemotherapy plasma sampling from patients who received ACT.
- In postoperative adjuvant chemotherapy, should the patient complete all cycles before submitting a plasma sample for ctDNA analysis?
- Are there circumstances when a ctDNA sample might be obtained on treatment?
Advertisement
Related to this article
Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Adding subcutaneous epcoritamab to R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.
A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.
The RASolute 309 trial is investigating frontline daraxonrasib plus the RAS G12D inhibitor zoldonrasib vs chemotherapy in advanced pancreatic ductal adenocarcinoma.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5